CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CTXR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	05:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/15	05:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/15	05:05	PR Newswire (US)	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/10	21:30	PR Newswire (US)	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/01	05:05	PR Newswire (US)	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/26	21:00	PR Newswire (US)	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/11	21:30	PR Newswire (US)	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/04	21:30	PR Newswire (US)	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/18	21:30	PR Newswire (US)	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/07	22:30	PR Newswire (US)	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/04	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/26	21:30	PR Newswire (US)	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/24	06:23	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/24	06:18	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/23	22:30	PR Newswire (US)	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	22:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	06:40	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	06:30	PR Newswire (US)	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/14	23:18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/14	22:01	PR Newswire (US)	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06:15	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06:08	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06:05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/24	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/23	22:30	PR Newswire (US)	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/06	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/03	06:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/02	22:31	PR Newswire (US)	Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/02	22:30	PR Newswire (US)	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2023/12/30	06:05	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CTXR	Citius Pharmaceuticals Inc